SHERIDAN, WYOMING - April 13, 2026 - Abbott's biosimilars medicines business is accelerating access to advanced biologic cancer therapies across emerging markets, where today only 0.1% of new biologic medicines are launched compared to 2%-3% penetration in developed markets. The disparity matters because emerging-market countries account for 57% of new cancer diagnoses globally and 65% of cancer deaths each year. Biosimilars - high-quality copies of approved biologic medicines with no meaningful difference in quality, safety, or efficacy - represent Abbott's core mechanism for closing that gap. With global cancer cases projected to climb from 20 million annually to more than 35 million by 2050, the business and public health stakes of biosimilar adoption are substantial.
The biologics access gap in emerging markets
Biologic medicines represent a distinct treatment class developed through biotechnology using living organisms such as bacteria or animal cells. Unlike conventional chemotherapy, which damages healthy and cancerous cells alike, biologics engage the immune system to target cancer cell growth selectively, leaving healthy tissue largely unharmed. That specificity has made biologics a preferred option for several cancer types where personalized, targeted therapy improves outcomes.
Despite their clinical advantages, biologics carry high development and manufacturing costs that price them out of reach for patients and healthcare systems in lower-income countries. Data from 2020 show that while biologics represented 2%-3% of total medicine volume in developed markets, fewer than 0.1% of newly launched biologics reached emerging markets. That access failure directly shapes survival rates, since the majority of cancer deaths occur in precisely those geographies.
How biosimilars change the equation
Biosimilars, which emerged as a regulatory category roughly 20 years ago, provide an approved pathway to offer biologic-equivalent therapies at lower cost. Regulators require biosimilars to demonstrate they are highly similar to their reference biologic with no clinically meaningful differences in quality, safety, or efficacy before approval. That standard enables healthcare systems to substitute biosimilars into treatment protocols with confidence, unlocking budget headroom for broader patient coverage.
The financial impact is documented at scale in Europe, where biosimilar competition has generated an estimated $64 billion in healthcare system savings since 2006. Those savings have allowed European payers to treat more patients within fixed budgets. Abbott's medicines division, led by Matthias Mueller as Head of Innovation and Development, is now directing that same model toward Latin America and other emerging regions, where regulatory framework harmonization is advancing adoption.
Patient outcomes and clinical evidence
Pablo Trochez, a patient in Bogota, Colombia diagnosed with Hodgkin's lymphoma, received a biosimilar as part of his treatment regimen. His oncologist prescribed the biosimilar after conventional chemotherapy planning had begun. Trochez responded well to the biosimilar therapy, and his cancer is currently under control - an outcome his care team attributes in part to the accessibility of the biosimilar option in the Colombian market.
Trochez's case is not presented as a guaranteed outcome, and Abbott explicitly notes that individual responses vary. However, the case illustrates the treatment pathway that biosimilar availability opens in markets where reference biologics would otherwise be unaffordable. Mueller has stated that increasing clinician and patient awareness, combined with more standardized regulatory frameworks across emerging countries, is the primary lever for scaling this access further.
Business impact
Procurement leads and formulary directors at hospital systems and health ministries across Latin America, Southeast Asia, and Sub-Saharan Africa face a direct decision point: biosimilar inclusion in national formularies and reimbursement lists now unlocks a therapy class that was structurally inaccessible a decade ago. The $64 billion savings precedent from Europe gives health economists a concrete benchmark for modeling budget scenarios in 2026 and forward procurement cycles, making biosimilar line items defensible in capital-constrained health budgets.
For pharmaceutical procurement officers and oncology supply chain directors, Abbott's expanding biosimilars portfolio in emerging markets signals a shift in vendor selection criteria. Contracts that previously defaulted to generic small-molecule oncology drugs must now evaluate biosimilar suppliers on regulatory approval status, cold-chain capability, and in-country distribution infrastructure. Technology roadmaps for hospital information systems will increasingly need to accommodate biosimilar substitution protocols at the point of prescribing, requiring integration work between pharmacy management platforms and electronic health records before 2027 formulary cycles close.